MedTech Strategist’s Post

Up next at #InnovationDublin24 is the “Syndication strategies among European VCs” Panel Session,” moderated by David Cassak of MedTech Strategist: • Evan Castiglia, Partner, Thuja Capital • Jeanne Bolger, Venture Partner, Seroba. • Janke Dittmer, Partner, Gilde Healthcare Key takeaways: • Syndication strategies among European VCs: Like a marathon, raising money requires time and energy, and different investors have the skill sets to help companies at different phases. So there is a tactical and strategic element to syndication. • When choosing syndication partners, the culture of a fund plays a role. How do they react when the company misses a milestone?  Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

Geoff Meyerson of Locust Walk, shared insights with Chief Medical Officer 360º on 2024 fundraising and business development trends. Discover how CMOs can enhance investor interactions. Don't miss advice for biotechs & CMOs navigating financing complexities.    Read the full article for a comprehensive overview and strategic outlook: https://lnkd.in/eMWjGXU8    #BiotechTrends #FinancialOutlook #CMOStrategies #InvestorRelations 

Great lessons for founders who are trying to raise capital from strategics Here's a great panel from #LSIEurope23 in Barcelona (MedTech and Digital Health) + Yassaman Salas, Head of MedTech Investment Banking at Goldman Sachs + Biren Mehta at Johnson & Johnson Ventures + Nate Harrington at Philips Ventures + Kevin Rocco (founder of Biorez) at CONMED Corporation! If you're going through M&A I suggest you learn from these #powerplayers about how they think through both sides of the table You NEED to learn how to create urgency for strategics if you're trying to sell or raise. Enjoy! --- Don P.S. If you like AR/VR, you'll love my weekly newsletter (free, duh). Weekly insights to help you pitch AR/VR investors, and more. Join 5,000+ subscribers here: https://bit.ly/48ggBGB

𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐫𝐞𝐚𝐝 𝐒𝐈𝐄 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐅𝐞𝐦𝐭𝐞𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭? 28 pages later and here are some key points that jumped out to me! 🌟 The Femtech sector as a whole, is projected to be worth over $𝟔𝟎𝐁𝐧 by 2027. 🌟 Leading regions in Europe for Femtech include the UK (31.8%), France (18.3%), Germany (12%), Sweden (7.9%) and Switzerland (5.5%). 🌟 Female founded Femtech start-ups raised $4.6M compared to $9.2M by those with all-male teams on average. 🌟 Investment in Women's Health has grown with deal counts up by 314% since 2018. 🌟 𝐎𝐧𝐥𝐲 𝟒% of all healthcare R&D is targeted at Women's Health issues specifically (🙄 *big sigh*). 🌟 Investing $300 million in women's health research = $𝟏𝟑 𝐁𝐈𝐋𝐋𝐈𝐎𝐍 for the US economy in the next 13-25 years. 🌟 𝐎𝐧𝐥𝐲 𝟏𝟓% of EU VC General Partners are women!! Worth a read to all my Femtech connections! If you have read it, what was most interesting to you? #femtech #vcfunding #sieventures Read the whole report here: https://lnkd.in/e4diNmEJ

M&A was the talk of the town at JPM week, but I'm also looking forward to hearing from our key medtech investment leaders on the lay of the land for early medtech funding in 2024. After a capital constrained 2023, this is a must attend session for early innovators looking for tips and tricks to leverage their innovation and maximise their attractiveness to investors. If you're a KOL interested in adding to this session, let me know! #medtech #innovation #LSXWorld

One day until DeviceTalks in Boston! I'm excited for tomorrow's panel on "How IP Can Drive Funding & Exits" moderated by David Dykeman from Greenberg Traurig, LLP. Here is what to expect: Join medtech VCs and CEOs as they delve into strategies for positioning your medtech company to attract investors, collaborators, and acquirers. Intellectual Property (IP) is critical for medtech companies to attract funding, strategic partners, and navigate an exit through M&A or IPO. To become attractive funding or M&A targets, medtech companies must prioritize de-risking and aligning their commercial, regulatory, and IP strategies. Gain insights into best practices and pitfalls to avoid when building strategic patent portfolios to close funding, stay competitive, and secure a successful exit. See you there! #DeviceTalksBoston #MedTech #IPstrategy

Now at #InnovationDublin24 is the “Where to Find Late Stage and Growth Capital and how the Game is Played” panel session moderated by David Cassak of MedTech Strategist:   ●     Susana Amorim Lopes, Investment Manager, Gilde Healthcare ●     Olivier Litzka, Partner, Andera Partners ●     Ruben Osnabrugge, Partner, 415 Capital ●     Alexander Schmitz, Partner, Endeavour Vision Q: How does today’s dearth of early-stage capital shape later stage investing?   A. I haven’t lost confidence in the medtech space. 90% of M&A still happens in the commercial stage, so there is a need for late stage capital. "It was easy to raise money during COVID, but now the tourists have left. So now it comes back to fundamentals." "In terms of exits, medtech is much less predictable than biotech, with fewer buyers here, which also have veiled agendas." Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

📣 Keeping The Cash Flow - Sustaining Momentum Through Maturation Join our panel of #MedtechLeaders as they discuss: ·  What trends or strategies do investors prioritize when assessing a medtech company's revenue outlook ·  How do successful medtech firms attract later-stage funding amid challenging economic conditions ·  Key considerations for medtech firms utilizing venture debt as a catalyst for sustained growth 🎙 Hear from: ·  David Kereiakes, Managing Partner, Windham Venture Partners ·  Darshana Zaveri, Managing Partner, Catalyst Health Ventures ·  Karthik Bolisetty, Senior Associate, Gilde Healthcare Find out more: https://lnkd.in/ey4UQiAP #LSXWorld 

Making Europe Competitive: Steps Toward a Pan-European Equity Market Ever wondered how Europe can rival the US in software? Henrik Molin, CEO & Co-founder of Physitrack PLC, shares his insights and experiences on leveraging public markets for growth. From Sweden's unique entrepreneurial landscape to six key initiatives that can transform Europe, Henrik's article provides a roadmap for creating a competitive and cohesive Pan-European equity market. Read the full article to explore actionable steps that can drive innovation and growth across Europe. Find the article here: https://lnkd.in/eQHQGDR2 #Boardwave #Makingwaves

📣 Investor Insights - Shaping Success for Early-Stage Ventures Join our panel of #MedtechLeaders as they discuss: · What strategies can early-stage medtech companies adopt to align with investor expectations for risk reduction and innovation · What are some successful strategies that early-stage medtech companies have employed to bridge the gap between initial funding and market viability · What specific attributes do you look for in medtech companies to determine their potential for reduced risk, scalability, and innovation 🎙 Hear from: ·  Jennifer McMahon, Partner, Seroba. Life Sciences ·  Diana Saraceni, General Partner, Panakes Partners ·  Klaus Stöckemann, Managing Director & Co-Founder, Peppermint Venture Partners GmbH Find out more: https://lnkd.in/efnAaEYC #LSXWorld